Full text not available from this repository.

Abstract

Background: Clinical studies have reported inconsistent outcomes of glucosamine therapy inosteoarthritis patients. One possible reason could be the use of glucosamine products of varyingquality. Hence, this study aimed to assess the quality of glucosamine products marketed inAustralia and India. This is the first study to investigate both the content and dissolutionprofiles of glucosamine products. Methods: The content and dissolution analysis of Australian(n=25 brands) and Indian (n=21 brands) glucosamine products was performed according to thecriteria specified in the United States Pharmacopoeia (USP). Results: The quality analysisrevealed that 16 and 18% of Australian brands, as well as 24 and 19% of Indian brands, did notfulfil the USP content and dissolution criteria, respectively. In approximately half of thesecases, the glucosamine content was only slightly below (Conclusions: The majority of the brands did meet both the content and dissolution analysis criteria of theUSP. The extent of deviation from the specified criteria for the other brands was probably insufficient to account for the significant variability in clinical effects. Hence, the studyproposed that inter-patient pharmacokinetic variations in glucosamine could be anotherpotential reason for inconsistent therapeutic effects.

Item Type:	Article
Authors/Creators:	Asthana, C and Peterson, GM and Shastri, MD and Patel, RP
Keywords:	glucosamine, quality, content-analysis, dissolution, osteoarthritis
Journal or Publication Title:	Journal of AOAC International
Publisher:	Oxford University Press
ISSN:	1944-7922
DOI / ID Number:	https://doi.org/10.1093/jaoacint/qsaa081
Copyright Information:	Copyright 2020 AOAC INTERNATIONAL
Related URLs:	UTAS Profile: Peterson, GM UTAS Profile: Shastri, MD UTAS Profile: Patel, RP
Item Statistics:	View statistics for this item

Actions (login required)

Item Control Page